Skip to content

Ultrasound-guided intra-articular injection of platelet rich plasma versus intra-articular injection of sodium hyaluronate in the treatment of knee osteoarthritis: a randomized, controlled, double-blind study

Ultrasound-guided intra-articular injection of platelet rich plasma versus intra-articular injection of sodium hyaluronate in the treatment of knee osteoarthritis: a randomized, controlled, double-blind study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029276
Enrollment
Unknown
Registered
2020-01-19
Start date
2019-04-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Experimental group:ultrasound guided intra-articular injection of PRP
Control group:ultrasound guided intra-articular injection of hyaluronic acid

Sponsors

Dept. of Rehabilitation Sciences, SunYat-Sen Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: We recruited 50- to 70-year-old patients with knee OA based on ACR criteria who complained of relevant symptoms for at least 6 months. The diagnosis and grading of OA were made after obtaining knee x-ray in anteroposterior weight-bearing and lateral views.

Exclusion criteria

Exclusion criteria: (1) pyogenic arthritis of the knee; (2) recent severe knee trauma; (3) hip or ankle disease; (4) rheumatism and rheumatoid arthritis; (5) hematological diseases, such as hemophilia, platelet dysfunction; (6) serious cardiovascular disease, immune system disease; (7) hemoglobin lower than 12g/dL or platelet count It was lower than 150,000/uL; (8) anticoagulant or antiplatelet drugs were taken within 10 days before injection; (9) hormone was taken within 2 weeks before injection; (10) sodium hyaluronate injection, hormone or platelet rich plasma therapy had been taken in the knee joint cavity within the previous year; (11) Allergic to the drugs used in the study.

Design outcomes

Primary

MeasureTime frame
WOMAC;

Secondary

MeasureTime frame
FSE T2WI;VAS;Quality of Life;

Countries

China

Contacts

Public ContactLi Xiao

Dept. of Rehabilitation Sciences, Sun Yat-Sen Memorial Hospital

1251149836@qq.com+86 15999951829

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026